Navigation Links
Targeted Nanoparticles Offer Promise in the Battle Against Cancer
Date:10/16/2007

RESEARCH TRIANGLE PARK, N.C., Oct. 16 /PRNewswire/ -- Liquidia Technologies announces a series of speaking engagements by company founder and University of North Carolina-Chapel Hill professor, Joseph DeSimone. At a series of events this fall, Dr. DeSimone will discuss drug delivery applications of the PRINT(TM) platform and his ongoing research in cancer therapeutics.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060614/CLW002LOGO )

-- Prostate Cancer Foundation Scientific Retreat - October 12, Lake Tahoe,

NV

-- NCI Nanotechnology Alliance Investigators Meeting - October 16, Chapel

Hill, NC

-- Williamsburg BioProcessing Foundation Conference - November 1, Austin,

TX

-- Nanomedicine & Drug Delivery Symposium - November 2, Boston, MA

-- Nanotechnology in Biology and Medicine Conference - November 5,

Charlotte, NC

-- American Chemical Society Workshop - November 7, Lake Tahoe, NV

"These engagements are a clear indication of the widespread commercial and scientific interest in the PRINT(TM) technology platform, developed by Dr. DeSimone and his colleagues," says Dr. Bill Weiser, General Manager of Pharmaceuticals at Liquidia. "The PRINT platform enables Liquidia and its licensees to develop novel engineered drug therapies based on precise nanoparticle design and scalable manufacturing capabilities."

DeSimone and researchers at Liquidia and UNC are exploring applications for the PRINT platform in a number of areas including delivery of oligonucleotides and cancer therapeutics. In collaboration with the National Cancer Institute (NCI), DeSimone is examining the effect of particle size and shape on cellular uptake, and the ability of specific ligands on the surface of a nanocarrier to promote cellular targeting.

During the 2007 Controlled Release Society Meeting, DeSimone presented data from a melanoma mouse model, in which 200 nm PRINT particles with aVb3 ligands successfully targeted the angiogenic tumor vasculature. Based on further pre-clinical studies, a PRINT-based cancer therapeutic is expected to enter clinical trials in 2008.

About Liquidia

Liquidia Technologies Inc. is an innovative nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a wide variety of life and materials science applications. Liquidia's proprietary PRINT(TM) platform is unique in its ability to replicate and produce nanoscale features with absolute control over particle size, shape, and composition. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina. For additional information, please visit http://www.liquidia.com.


'/>"/>
SOURCE Liquidia Technologies
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
7. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
9. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... PUNE, India , January 16, 2017 /PRNewswire/ ... by Allied Market Research, titled, "Sterilization Technologies Market by ... Forecast, 2014-2022," the global sterilization technologies market is expected ... in 2015, growing at a CAGR of 5.8% from ... dominated the market in 2015, with more than half ...
(Date:1/16/2017)... January 16, 2017 Bill is an internationally ... general management and leadership positions with global medical device companies, including ... track record of launching new products and building successful businesses in ... Africa and North America ... Educated at ...
(Date:1/16/2017)... -- CBDRx, the world,s premiere nutraceutical hemp company, is ... extract to Veteran,s groups across the country. ... to Veteran,s groups across the United States.  Passion is ... world and through their passion, CBDRx honors our Veterans ... hemp extract available. ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for a ... video released by Serenity Recovery, a holistic treatment center for addiction located in Marne, ... footage and testimonials from patients and staff that visited the 2016 Recovery Palooza support ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... Seating. Prairie’s award-winning Reflection® brand of custom seating systems has a well-earned reputation ... Permobil with a platform for innovation and growth in the custom seating business, ...
(Date:1/16/2017)... ... January 16, 2017 , ... St. Louisans are well-aware of the following facts at ... This year’s influenza shot seems to be having no effect on keeping this particularly bad ... of the people around are coughing, sneezing, or sniffling , These facts ...
(Date:1/16/2017)... Pekin, IL (PRWEB) , ... January 16, 2017 ... ... Professionals (iaedp) organized to provide first-quality education and high-level training standards to an ... full spectrum of eating disorder problems. As a way to further its mission ...
(Date:1/16/2017)... ... January 16, 2017 , ... Vixiar ... Officer of the medical device company, effective immediately. , “This is perfect timing ... has a strong track record in medical device market development and revenue growth, ...
Breaking Medicine News(10 mins):